Clariness will support Bayer Pharma AG’s new study review process, which combines international insights from patients, investigators, and independent bodies. While traditionally Pharmabiotech companies only gather limited insights and feedback from a few parties, and on a regional level, this international and holistic approach is believed to be the future of study reviews.